Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb 3;26(1):24.
doi: 10.1186/s10194-025-01961-0.

Epidemiology of clinically significant migraine in Israel: a retrospective database study

A Shifrin  1 , E Domany  1 , M Tirosh  2 , D Davidovici  2 , S Vinker  3 , I Forschner  4 , A Israel  5   6
Affiliations

Epidemiology of clinically significant migraine in Israel: a retrospective database study

A Shifrin et al. J Headache Pain. .

Abstract

Background: Epidemiological studies on migraine are valuable for tracking disease trends, identifying risk factors, and informing treatment strategies. This study assessed the prevalence and annual incidence of clinically significant migraine in Israel from 2017 to 2022, with analyses stratified by age, sex, socioeconomic status, and district. Additionally, we compared relevant characteristics between adult migraine and non-migraine members of Leumit Healthcare Services (LHS), a national health provider in Israel.

Methods: This retrospective study used LHS electronic health records to evaluate migraine prevalence and annual incidence from 2017 to 2022 among adult LHS members. Clinically significant migraine patients were identified using stringent criteria, including repeated diagnostic codes for migraine, confirmation by a neurologist, or the use of migraine-specific therapies. Each migraine patient was matched 1:1 with a control individual of similar age, sex, socioeconomic status, and ethnic background.

Results: The prevalence of clinically significant migraine increased from 4.5% in 2017 to 5.2% in 2022, with significantly higher rates in women compared to men (8% vs. 2.4% in 2022). The mean age of migraine patients was 46.8 years in 2022. The annual incidence of migraine in 2022 was 43 per 10,000 individuals over 18, with approximately 75% of new cases occurring in women, with a mean age of 36.5 years. The annual incidence of migraine slightly decreased over the period. Approximately two-thirds of new patients were diagnosed by neurologists, with only 19% diagnosed by family physicians. Compared to a matched control population, migraine patients showed a higher prevalence of low body mass index (BMI) and higher diastolic blood pressure (BP). Additionally, distinct differences in laboratory findings were observed among migraine patients, notably lower glucose and hemoglobin A1c levels, lower rate of microalbuminuria, with higher hemoglobin, which may be associated with migraine pathophysiology.

Conclusion: This study provides a detailed epidemiological and clinical profile of patients with clinically significant migraine in LHS from 2017 to 2022. Notable trends include higher rates of migraine among patients with lower BMI, higher diastolic BP, lower glucose, and higher hemoglobin, suggesting potential modifiable risk factors.

Keywords: Israel; Migraine; Migraine epidemiology; Migraine incidence; Migraine prevalence.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was approved by the ethics committee of Leumit Health Services (LEU 0008–23) with a waiver of informed consent. Consent for publication: Not applicable. Competing interests: A.S is an employee of Rambam Healthcare Campus who was paid as a consultant to Pfizer in connection with this study, M. T and D. D are employees of Pfizer pharmaceuticals Israel LTD. The remaining authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1
Prevalence of clinically significant migraine by year and sex
Fig. 2
Fig. 2
Prevalence of clinically significant migraine by year, sex, and age category
Fig. 3
Fig. 3
Prevalence of clinically significant migraine by year and regional district
See this image and copyright information in PMC

References

    1. Croop R, Goadsby PJ, Stock DA et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet 394:737–745 - PubMed
    1. GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024 Apr;23(4):344–381. 10.1016/S1474-4422(24)00038-3. Epub 2024 Mar 14. Erratum in: Lancet Neurol. 2024 May;23(5):e9. 10.1016/S1474-4422(24)00114-5. Erratum in: Lancet Neurol. 2024 Jul;23(7):e11. 10.1016/S1474-4422(24)00231-X. PMID: 38493795; PMCID: PMC10949203. - PMC - PubMed
    1. Spindler BL, Ryan M (2020) Medications approved for preventing migraine headaches. Am J Med 133:664–667. 10.1016/j.amjmed.2020.01.031 - PubMed
    1. Burch RC, Loder S, Loder E, Smitherman TA (2015) The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache J Head Face Pain 55:21–34. 10.1111/head.12482 - PubMed
    1. Lipton RB, Bigal ME, Diamond M et al (2007) Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68:343–349. 10.1212/01.wnl.0000252808.97649.21 - PubMed

LinkOut - more resources